Table 4.
Other lipid lowering medications' drug-drug interactions with medications used for COVID-19 or assessed in clinical trials and recommendations.
| Ezetimibe [147,148] | PCSK9 inhibitors [75] | Omega-3- fatty acids | Lomitapide [116] | |
|---|---|---|---|---|
| Remdesivir | Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
Not directly studied Recommend: to withhold treatment temporarily |
| Hydroxychloroquine | Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
NSI Recommend: Continue [149] |
Not directly studied Recommend: to withhold treatment temporarily |
| Lopinavir | Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
NSI Recommend: Continue [150] |
Lopinavir is predicted to markedly increase the exposure to lomitapide and risk of hepatotoxicity Recommend: to withhold treatment temporarily |
| Ritonavir | Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
NSI Recommend: Continue [150] |
Ritonavir is predicted to markedly increase the exposure to lomitapide and risk of hepatotoxicity Recommend: to withhold treatment temporarily |
| Ribavirin | Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
NSI Recommend: Continue [[151], [152], [153]] |
Not directly studied. Recommend: to withhold treatment temporarily |
| Interferon-Beta 1 -Alpha | Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
NSI Recommend: Continue [154,155] |
Increased risk of hepatoxicity. Recommend: to withhold treatment temporarily |
|
Melatonin |
Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
Not directly studied Recommend: to withhold treatment temporarily |
|
Dexamethasone |
Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
NSI Recommend: Continue |
Not directly studied Recommend: to withhold treatment temporarily. |
| Azithromycin | Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
NSI Recommend: Continue [156] |
Azithromycin is a weak CYP3A4 inhibitor and is predicted to increase exposure to lomitapide Recommend: to withhold treatment temporarily |
| Tocilizumab | Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
Not directly studied Recommend: to withhold treatment temporarily |
| Ivermectin | Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
Not directly studied but likely safe Recommend: Continue |
Not directly studies. Some references suggest that lomitapide may slightly increase levels of ivermectin Recommend: to withhold treatment temporarily |
We recommend stopping niacin in acutely ill patients with COVID-19.
For other drugs potential interactions please visit https://www.hiv-druginteractions.org/ also BNF, Stockley's Drug Interactions, individual drugs SmPC and consult with your pharmacy department.
NSI: no significant interactions.